Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

被引：2
|
作者：
Jaggers, Jordon [1 ]
Klepin, Heidi D. [2 ]
Wildes, Tanya M. [3 ]
Olin, Rebecca L. [4 ]
Artz, Andrew S. [5 ]
Wall, Sarah A. [6 ]
Jaglowski, Samantha [6 ]
William, Basem M. [6 ]
Benson, Don M., Jr. [6 ]
Rosko, Ashley E. [6 ]
机构：
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Wake Forest Sch Med, Winston Salem, NC 27101 USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] City Hope Comprehens Canc Ctr, Duarte, CA USA
[6] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131504
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5819
引用
收藏
页数：3
相关论文
共 45 条
  • [1] Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies
    Jaggers, Jordon L.
    Giri, Smith
    Klepin, Heidi D.
    Wildes, Tanya M.
    Olin, Rebecca L.
    Artz, Andrew
    Wall, Sarah
    Jaglowski, Samantha
    William, Basem
    Benson, Don M.
    Rosko, Ashley E.
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (02) : 235 - 238
  • [2] Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
    Lin, Wen-Ying
    Wang, Hsin-Hui
    Chen, Yi-Wei
    Lin, Chun-Fu
    Fan, Hueng-Chuen
    Lee, Yi-Yen
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 21
  • [3] Current status of CAR-T cell therapy for pediatric hematologic malignancies
    Hidefumi Hiramatsu
    [J]. International Journal of Clinical Oncology, 2023, 28 : 729 - 735
  • [4] Current status of CAR-T cell therapy for pediatric hematologic malignancies
    Hiramatsu, Hidefumi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (06) : 729 - 735
  • [5] Editorial: Efficacy and safety of CAR-T cell therapy in hematologic malignancies
    de Lima, Marcos
    Di Rocco, Alice
    Ribera, Jose-Maria
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [6] Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
    Hao Wang
    Gurbakhash Kaur
    Alexander I. Sankin
    Fuxiang Chen
    Fangxia Guan
    Xingxing Zang
    [J]. Journal of Hematology & Oncology, 12
  • [7] Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
    Wang, Hao
    Kaur, Gurbakhash
    Sankin, Alexander I.
    Chen, Fuxiang
    Guan, Fangxia
    Zang, Xingxing
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [8] Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies
    Huang, Yuxian
    Qin, Yinjie
    He, Yingzhi
    Qiu, Dezhi
    Zheng, Yeqin
    Wei, Jiayue
    Zhang, Lenghe
    Yang, Dong-Hua
    Li, Yuhua
    [J]. DRUG RESISTANCE UPDATES, 2024, 74
  • [9] Underrepresentation of Older Adults in Clinical Trials of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hematologic Malignancies: An FDA Analysis
    Seam, Pamela
    Mahat, Upendra
    Bouchkouj, Najat
    Sharma, Poornima
    Peredo-Pinto, Helka
    Elmacken, Mona
    Kaushal, Megha
    Jia, Yuxia
    Wang, Shu
    Xu, Zhiheng
    Kasamon, Yvette
    Kanaparu, Bindu
    Richardson, Nicholas
    Gormley, Nicole
    [J]. BLOOD, 2023, 142
  • [10] Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations
    Wang, Le
    [J]. CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2022, 70 (01)
12345